Related Experiment Video
Updated: Sep 13, 2025
Single Molecule Analysis of Laser Localized Psoralen Adducts
Published on: April 20, 2017
Laser-Induced Dimeric Photoproducts of Chlorpromazine: LC-MS Identification and Molecular Docking Evidence of
Ana-Maria Udrea1,2, Florin Bilea1, Speranta Avram2
1National Institute for Lasers, Plasma and Radiation Physics, 409 Atomistilor Str., 077125 Magurele, Romania.
Abstract:
Breast cancer treatments, such as chemotherapy, radiation, and surgery, often face significant limitations, highlighting the need for more effective and targeted therapies. Here, we investigate the potential of 266 nm laser irradiation of chlorpromazine as a novel approach to develop new antitumoral compounds. We identify six chlorpromazine photocompounds with masses in the range of 178-334 u, along with several dimeric compounds with masses between 566 and 600 u, using an HPLC-MS. In silico approaches assess their pharmacokinetic and pharmacodynamic properties while comparing their toxicity with the parent compound. Molecular docking simulations indicate that some photoproducts have a low estimated free energy of binding to cancer-related targets, suggesting enhanced therapeutic potential compared to chlorpromazine. Additionally, ADME-Tox predictions indicate that these photoproducts may have pharmacokinetic and toxicity profiles similar to chlorpromazine. Overall, this study highlights that laser-generated chlorpromazine photoproducts exhibit enhanced biological activity to breast cancer-related targets compared to chlorpromazine while maintaining a similar ADME-Tox profile.
Insights
Laser irradiation of chlorpromazine created new compounds with enhanced anti-breast cancer activity. These novel photoproducts show potential for targeted therapies with similar safety profiles to the original drug.
Area of Science:
- Photochemistry
- Medicinal Chemistry
- Oncology
Background:
- Current breast cancer treatments face limitations, necessitating novel therapeutic strategies.
- There is a need for more effective and targeted antitumoral compounds.
Purpose of the Study:
- To investigate 266 nm laser irradiation of chlorpromazine for novel antitumoral compound development.
- To assess the therapeutic potential and safety of laser-generated chlorpromazine photoproducts.
Main Methods:
- High-performance liquid chromatography-mass spectrometry (HPLC-MS) to identify photoproducts.
- In silico methods including pharmacokinetic/pharmacodynamic assessments and molecular docking.
- ADME-Tox predictions to evaluate safety profiles.
Main Results:
- Six chlorpromazine photoproducts (178-334 u) and dimeric compounds (566-600 u) were identified.
- Molecular docking revealed low binding free energy to cancer targets for some photoproducts.
- In silico predictions suggested similar pharmacokinetic and toxicity profiles to chlorpromazine.
Conclusions:
- Laser-generated chlorpromazine photoproducts demonstrate enhanced biological activity against breast cancer targets.
- These photoproducts represent a promising avenue for developing novel breast cancer therapies.
- The study indicates potential for improved efficacy with a comparable safety profile to chlorpromazine.
